Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.75 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL30940372 | 0.99 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL15164805 | 0.91 | CYP3A4 (0.78) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL15164819 | 0.91 | CYP3A4 (0.78) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL16440228 | 0.90 | CYP3A4 (0.77) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL9914888 | 0.88 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL9914890 | 0.88 | CYP2D6 (0.75) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL9914945 | 0.87 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL14754253 | 0.86 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL13464991 | 0.86 | CYP2C19 (0.88) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 | |
| SCHEMBL9914891 | 0.86 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2D6CYP1A2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137495-A9 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-07-25 | — | — | WO | claimed |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | NAVINTA, LLC | 2024-06-27 | — | — | US | claimed |
| WO-2024137495-A1 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2024137495-A9 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024137495-A1 | FOSTEMSAVIR INTERMEDIATES AND PROCESS FOR THE PREPARATION THEREOF | NAVINTA, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | NAVINTA, LLC | 2024-06-27 | — | — | US | disclosed |
| EP-2646439-B1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2646439-B1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8912195-B2 | Alkyl amides as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912195-B2 | Alkyl amides as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912195-B2 | Alkyl amides as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252968-A1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252968-A1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252968-A1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075235-A1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252968-A1 | ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS | NAPA, ASNS, CD4 | CYP3A4 164/4885CYP2C9 500/4885CYP2D6 403/4885 |
| US-20240208980-A1 | Fostemsavir Intermediates and Process for the Preparation Thereof | FIP1L1, CYP3A4, FOS | CYP3A4 2/4885CYP2C9 18/4885CYP2D6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.